Due to its properties and the ability to reduce glycated hemoglobin by 1–2%, GLP-1 has become important in the treatment of T2D as an analogous drug with heterogeneous pharmacokinetic patterns [73]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.